J&J files in Europe for first-line Imbruvica use in CLL; First-to-market races mean small R&D leads can pay off big;

> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release

> These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report

> Johnson & Johnson and GlaxoSmithKline's ($GSK) ViiV Healthcare joint venture touted data from Phase II studies of two long-acting injectable versions of now-daily HIV pills. Release | Report

And Finally ... Mylan ($MYL) won U.S. antitrust approval to buy Perrigo ($PRGO), provided it sells off rights to several generic products. Release

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.